斯托克新闻网开始对Antares制药公司(纳斯达克：ATRS)进行报道

Research analysts at StockNews.com started coverage on shares of Antares Pharma (NASDAQ:ATRS – Get Rating) in a research note issued on Tuesday. The brokerage set a "sell" rating on the specialty pharmaceutical company's stock.

Several other brokerages have also weighed in on ATRS. Piper Sandler lowered Antares Pharma from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $6.00 to $5.60 in a research report on Thursday, April 14th. LADENBURG THALM/SH SH lowered Antares Pharma from a "buy" rating to a "neutral" rating in a research report on Thursday, April 14th. Raymond James lowered Antares Pharma from a "strong-buy" rating to a "market perform" rating in a research report on Thursday, April 14th. HC Wainwright lowered Antares Pharma from a "buy" rating to a "neutral" rating and set a $5.60 price objective on the stock. in a research report on Thursday, April 14th. Finally, Truist Financial lowered Antares Pharma from a "buy" rating to a "hold" rating and cut their price objective for the company from $7.00 to $5.60 in a research report on Wednesday, April 13th. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $5.60.

Get

Antares Pharma

alerts:

ATRS stock opened at $5.59 on Tuesday. Antares Pharma has a 52-week low of $3.11 and a 52-week high of $5.60. The stock's fifty day simple moving average is $5.58 and its 200-day simple moving average is $4.37. The company has a quick ratio of 2.87, a current ratio of 3.08 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $955.06 million, a price-to-earnings ratio of 23.29 and a beta of 1.15.

Antares Pharma (NASDAQ:ATRS – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $41.56 million for the quarter, compared to analyst estimates of $44.01 million. Antares Pharma had a return on equity of 7.43% and a net margin of 21.90%. As a group, analysts anticipate that Antares Pharma will post 0.08 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in ATRS. CWM LLC purchased a new stake in shares of Antares Pharma during the fourth quarter worth about $117,000. Russell Investments Group Ltd. increased its position in shares of Antares Pharma by 226.8% during the fourth quarter. Russell Investments Group Ltd. now owns 1,142,491 shares of the specialty pharmaceutical company's stock worth $4,077,000 after acquiring an additional 792,898 shares during the last quarter. Clear Harbor Asset Management LLC increased its position in shares of Antares Pharma by 40.0% during the fourth quarter. Clear Harbor Asset Management LLC now owns 36,400 shares of the specialty pharmaceutical company's stock worth $130,000 after acquiring an additional 10,400 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Antares Pharma by 18.1% during the third quarter. Dimensional Fund Advisors LP now owns 1,671,494 shares of the specialty pharmaceutical company's stock worth $6,084,000 after acquiring an additional 255,995 shares during the last quarter. Finally, JT Stratford LLC purchased a new stake in shares of Antares Pharma during the fourth quarter worth about $62,000. 50.41% of the stock is currently owned by institutional investors.

Antares Pharma Company Profile (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Further Reading

• Get a free copy of the StockNews.com research report on Antares Pharma (ATRS)
• Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
• Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
• MarketBeat: Week in Review 6/27 – 7/1
• Accolade Moves Higher But Growth Is Slowing
• ZIM Integrated Shipping Services (ZIM): Don't Miss This Dividend

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.